Breast cancer intrinsic subtype classification, clinical use and future trends.
By Xiaofeng Dai, Ting Li, Zhonghu Bai, Yankun Yang, Xiuxia Liu, Jinling Zhan, Bozhi Shi. American Journal of Cancer Research, 2015
909 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/fa92af436a7d04fcccc025fdedde4039d19df42f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Nikos Koundouros
- C. Condrat
- G. Poulogiannis
- Hongye Cheng
- D. Thompson
- Xiaofeng Dai
- Zhonghu Bai
- Jia Li
Citations in the corpus
- miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis (2020, background): “Because of the generally poorer prognosis of TNBC, research has been focused lately on the discovery of biomarkers of breast cancer subtypes.”
- Reprogramming of fatty acid metabolism in cancer (2019, background): “The regulatory complexity of lipid metabolism in the context of molecular heterogeneity is perhaps best exemplified in breast cancer, which comprises multiple different subtypes characterised by unique hormone/growth-factor receptor expression and genetic profiles.(71) Comparative mRNA expression an”
- Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping (2017, background): “Unlike at the tissue level where luminal tumors dominate (63% [50]), cell lines of this subtype take the least percentage (31%) among all, i.”